Information Provided By: 
Fly News Breaks for August 6, 2015
KERX
Aug 6, 2015 | 08:02 EDT
JPMorgan says its research indicates doctors will likely increase Auryxia use as they gain more experience and comfort with the drug. After surveying 25 doctors, the firm believes Auryxia's dual phosphorus/iron benefit will prove attractive to prescribers. It lowered its price target for Keryx shares to $17 from $19 and keeps an Overweight rating on the name.
News For KERX From the Last 2 Days
There are no results for your query KERX
